A pretreatment mass spectrometry-based serum proteomic test is able to stratify patients with ovarian cancer receiving adjuvant chemotherapy according to overall and progression-free survival and identify patients likely to exhibit chemoresistance
Kasimir-Bauer, S., Krivak, T.C., Herzog, T., Steingrimsson, A., Roder, H., Roder, J.Volume:
145
Language:
english
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2017.03.193
Date:
June, 2017
File:
PDF, 138 KB
english, 2017